Cabo Verde Business Journal
SEE OTHER BRANDS

Following business and economy news from Cabo Verde

Cabo Verde Business Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Cabo Verde Business Journal.

Press releases published on April 28, 2025

Smart Share Global Limited Files Its Annual Report on Form 20-F

Smart Share Global Limited Files Its Annual Report on Form 20-F

SHANGHAI, April 28, 2025 (GLOBE NEWSWIRE) -- Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced that it filed its annual report on Form 20-F for the …

ASML reports transactions under its current share buyback program

ASML reports transactions under its current share buyback program

ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. Date Total repurchased shares Weighted average …

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in these models. Tovecimig in …

Les prix Cpl. Cumming's Watch de MADD Canada honorent les efforts des policiers de l'Alberta pour leur lutte contre la conduite aux capacités affaiblies

Les prix Cpl. Cumming's Watch de MADD Canada honorent les efforts des policiers de l'Alberta pour leur lutte contre la conduite aux capacités affaiblies

EDMONTON, Alberta, 28 avr. 2025 (GLOBE NEWSWIRE) -- Au cours d'une cérémonie qui se tiendra à Edmonton, MADD Canada décernera les prix Cpl. Cumming's Watch à 68 policiers qui se sont surpassés pour retirer les conducteurs aux capacités affaiblies des …

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

Presentations at WHS and SAWC to highlight EscharEx’s mechanism of action, preclinical advantages over SANTYL®, and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III study in VLUs and support the planned DFU trial strategy YAVNE, …

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025

First gamma-delta (γδ) TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine release syndrome (CRS) INB-600 TCE …

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

New data includes real-world analyses of VOQUEZNA-treated patients in the U.S. diagnosed with gastroesophageal reflux disease (GERD) FLORHAM PARK, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical …

The Secret Tool Hair Loss Providers Use to Treat Their Own Hair Loss?

The Secret Tool Hair Loss Providers Use to Treat Their Own Hair Loss?

CLEVELAND, April 28, 2025 (GLOBE NEWSWIRE) -- The Secret Is Out — And It’s Surprisingly Simple When it comes to hair loss, you’d think the professionals who spend their lives treating it have all the answers. Access to the best clinics, the latest …

Embecta to host Analyst and Investor Day on May 22, 2025

Embecta to host Analyst and Investor Day on May 22, 2025

PARSIPPANY, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will hold an Analyst and Investor Day on May 22, 2025, from 9:00 a.m. to 12:30 p.m. in …

Veri Medtech (VRHI) Retains PCAOB Auditor

Veri Medtech (VRHI) Retains PCAOB Auditor

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Veri Medtech Holdings, Inc. (OTC Markets: (“VRHI”) ("Veri Medtech") announced today that it has retained Salberg …

Montage Gold Announces Graduation to the Toronto Stock Exchange

Montage Gold Announces Graduation to the Toronto Stock Exchange

VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Montage Gold Corp. (“Montage” or the “Company”) (TSXV: MAU, OTCQX: MAUTF) is pleased to announce that it has received final approval from the Toronto Stock Exchange ("TSX") for the listing of …

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+™ Development

Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very heavily pretreated patients Clinical benefit observed in 83% of evaluable patient sub-group treated with the phase 3 formulation Improved new Bria …

EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease

EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease

Initial real-world data from nearly 40,000 EYLEA HD patients will provide early insights on effectiveness of EYLEA HD in everyday clinical practice New indirect comparisons will evaluate EYLEA HD and faricimab on measures of efficacy, dosing frequency and …

AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening

AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening

LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, and EmeritusDX, a rapidly growing cancer …

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will report its first quarter 2025 financial …

Matador Technologies Inc. Announces Symbol Change and DTC Eligibility of its Common Shares

Matador Technologies Inc. Announces Symbol Change and DTC Eligibility of its Common Shares

TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Matador Technologies Inc. (“Matador” or the “Company”) (TSXV: MATA, OTCQB: MATAF), a Bitcoin Ecosystem company, is pleased to announce that the Company’s stock ticker symbol on the OTCQB Venture Market (the “ …

Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML

Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best overall response evaluable patients …

Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax

Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax

ROCKVILLE, Md. and SUZHOU, China, April 28, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs …

G2 Continues to Expand New Surface Gold Discovery and Provides Exploration Update

G2 Continues to Expand New Surface Gold Discovery and Provides Exploration Update

G2 drills 41m @ 1.2 g/t Au …

Beamr to Participate in Upcoming Investor Conferences in May 2025

Beamr to Participate in Upcoming Investor Conferences in May 2025

Beamr will present at the Ladenburg Thalmann Technology Innovation Expo in New York, and participate virtually in the Needham 1x1 Conference  Herzliya, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Beamr Imaging Ltd. (NASDAQ: BMR), a leader in video …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service